Status:
ACTIVE_NOT_RECRUITING
Single-Cell Sequence Technology Used to Reveal Heterogeneity of Secondary Hyperparathyroidism
Lead Sponsor:
China-Japan Friendship Hospital
Conditions:
Secondary Hyperparathyroidism
Eligibility:
All Genders
18-80 years
Brief Summary
This project intends to select cases that meet the research requirements, take secondary hyperparathyroidism, primary hyperparathyroidism and normal human parathyroid tissue, a total of three groups, ...
Eligibility Criteria
Inclusion
- Study participants with a diagnosis of secondary hyperparathyroidism who underwent surgical treatment
- Study participants with a diagnosis of primary hyperparathyroidism who underwent surgical treatment
- Study participants who have obtained informed consent
Exclusion
- Other non-secondary hyperparathyroidism conditions such as primary hyperparathyroidism were excluded at the time of inclusion of study participants with essential hyperparathyroidism.
- Other non-primary hyperparathyroid conditions such as secondary hyperparathyroidism were excluded at the time of inclusion of study participants with essential hyperparathyroidism.
- Refusal of informed consent.
Key Trial Info
Start Date :
November 10 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2025
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT06130683
Start Date
November 10 2023
End Date
July 31 2025
Last Update
December 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China and Japan Friendship Hospital
Beijing, China